The need for novel anti-infective therapies is dramatically increasing, not only for viral but also for bacterial infections and antimicrobial resistance. This is especially true for chronic lung infections, typically occurring during e.g., cystic fibrosis (CF). Mimicking the structure and physiology of the diseased lung, advanced in vitro models also allow studying the pathophysiological changes relevant to microbial growth, drug resistance, and biofilm formation. Combining data from such advanced in vitro models with pharmacometric approaches may enable mechanistic explanation of the PK/PD drug exposure-response relationship and facilitate the translation to an in vivo setting.

对新型抗感染疗法的需求正在急剧增加，不仅针对病毒感染，还针对细菌感染和抗微生物药物耐药性。对于慢性肺部感染尤其如此，通常发生在例如囊性纤维化 (CF) 期间。模拟患病肺的结构和生理学，先进的体外模型还允许研究与微生物生长、耐药性和生物膜形成相关的病理生理变化。将来自此类先进体外模型的数据与药理学方法相结合，可以对 PK/PD 药物暴露-反应关系进行机械解释，并促进转化为体内环境。